CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease

-



Invalid Access Key!

Invalid Access Key!


Comments

Post a Comment

Popular posts from this blog

Diagnosis and management of vascular Ehlers-Danlos syndrome: Experience of the UK national diagnostic service, Sheffield | European Journal of Human Genetics

-
Image
blood disease myeloma :: Article Creator Rare Blood Disease Innovations Address Unmet Needs, According To ASH Data Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma. Innovations in rare blood disorders took center stage at ASH 2024. Image Credit: shidlovski-stock.Adobe.Com Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with Sanofi highlighting 49 abstracts, including 9 oral presentations, featured at the conference in San Diego.1 Key research was presented on immune thrombocytopenia (ITP), hemophilia, and multiple myeloma (MM), among other disease states. With new findings related to approved and investigational therapies alike, the diverse portfolio demonstrates the e...
Read more

Non-invasive prenatal testing: a revolutionary journey in prenatal testing

-
Image
factor ix deficiency :: Article Creator Novo Nordisk Files Long-acting Factor IX For Haemophilia B In US Novo Nordisk has filed its long-acting factor IX, nonacog beta pegol in the US for haemophilia B. Nonacog beta pegol is a glycopegylated recombinant factor IX with a longer half-life, developed for patients with haemophilia B. Novo said that the drug's half-life is five times longer than standard factor IX products, meaning fewer injections are needed. Although Novo has long had a presence in haemophilia, it faces competition in both haemophilia A and B. In haemophilia B, Biogen and Swedish Orphan Biovitrum have Alprolix (coagulation factor IX (recombinant)) approved in the EU and the US. The filing of nonacog beta pegol is based on the results from the PARADIGM clinical trial programme which involved 115 patients with severe or moderately severe haemophilia B. Nonacog beta pegol was found to be efficacious in routine prophylaxis, treat...
Read more

Adeno-associated virus as a delivery vector for gene therapy of human diseases

-
Image
hemophilia c :: Article Creator Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies And Breakthrough Therapies Shaping The Future Landscape (MENAFN- GetNews) DelveInsight's, "Hemophilia Pipeline Insight, 2025," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report Key Takeaways from the Hemophilia Pipeline Report In July 2025, Novo Nordisk A/S announce...
Read more